Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01799824 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis
A Phase 2 study of Primary Axillary Hyperhidrosis, sponsored by Anterios.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 9
- Study locations
NCT01799824 is a Phase 2 study of Primary Axillary Hyperhidrosis that has completed, run by Anterios. The registered enrollment target is 52 participants. The trial reports 9 study locations across 7 states.
The verdict
NCT01799824, a Phase 2 study of Primary Axillary Hyperhidrosis, has completed, sponsored by Anterios.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to confirm the effect of ANT-1403 in the treatment of primary axillary hyperhidrosis.
Conditions Studied
Interventions
- BIOLOGICAL placebo
- BIOLOGICAL ANT-1403
Study Locations (9)
Florida
- - Miami
- - Pinellas Park
- - West Palm Beach
Kentucky
- - Louisville
New Jersey
- - East Windsor
New York
- - Rochester
North Carolina
- - Raleigh
Pennsylvania
- - Yardley
Virginia
- - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01799824
The ClinicalTrials.gov registry entry for NCT01799824 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anterios, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Axillary Hyperhidrosis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01799824 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Florida, Kentucky, New Jersey.
Frequently Asked Questions
What is clinical trial NCT01799824 about?
NCT01799824 is a clinical study titled "Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis". The purpose of this study is to confirm the effect of ANT-1403 in the treatment of primary axillary hyperhidrosis.
What is the current status of trial NCT01799824?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2013-02. Estimated completion is 2013-07.
What conditions does trial NCT01799824 study?
This clinical trial studies the following conditions: Primary Axillary Hyperhidrosis.
What interventions are being tested in trial NCT01799824?
The interventions under investigation include: placebo (BIOLOGICAL), ANT-1403 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01799824?
This trial is sponsored by Anterios, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01799824 being conducted?
This trial has 9 study locations across Florida, Kentucky, New Jersey, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.